Option chain shows key data for Terran Orbital Corp Warrants (09/03/2028)'s stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Terran Orbital Corp Warrants (09/03/2028).

Terran Orbital Corp Warrants (09/03/2028) (OTC:LLAPW) Stock, Option Chain

Terran Orbital Corp Warrants (09/03/2028)

<p>Providing a diverse range of perspectives from bullish to bearish, 10 analysts have published ratings on BlackLine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BL#NASDAQ">BL</a>) in the last three months.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for BlackLine, revealing an average target of $71.3, a high estimate of $86.00, and a low estimate of $60.00. Witnessing a positive shift, the current average has risen by 9.69% from the previous average price target of $65.00.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1738274443_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>A comprehensive examination of how financial experts perceive BlackLine is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Koji Ikeda</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$75.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Steven Enders</td>
<td>Citigroup</td>
<td>Maintains</td>
<td>Buy</td>
<td>$73.00</td>
<td>$73.00</td>
</tr>
<tr>
<td>Patrick Walravens</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$86.00</td>
<td>$86.00</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Underweight</td>
<td>$60.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Steven Enders</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$73.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Patrick Walravens</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$86.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$60.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Chris Quintero</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$80.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Terry Tillman</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$60.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$60.00</td>
<td>$51.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to BlackLine. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of BlackLine compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of BlackLine's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Capture valuable insights into BlackLine's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/BL/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on BlackLine analyst ratings.</strong></a></p>
<h2>About BlackLine</h2>
<p>BlackLine Inc is engaged in providing financial accounting close solutions delivered as Software as a Service (SaaS). The Company's solutions enable its customers to address various aspects of their financial close process including account reconciliations, variance analysis of account balances, journal entry capabilities, and certain types of data matching capabilities. The majority of the revenue of the company is earned in the United States.</p>
<h3>BlackLine's Economic Impact: An Analysis</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> BlackLine's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of <strong>10.09%</strong>. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Information Technology sector.</p>
<p><strong>Net Margin:</strong> BlackLine's net margin is impressive, surpassing industry averages. With a net margin of <strong>10.39%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>4.97%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> BlackLine's ROA excels beyond industry benchmarks, reaching <strong>0.96%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of <strong>2.49</strong>, caution is advised due to increased financial risk.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings

Beyond The Numbers: 10 Analysts Discuss BlackLine Stock

<p>4 analysts have shared their evaluations of UMB Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UMBF#NASDAQ">UMBF</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $141.5, a high estimate of $156.00, and a low estimate of $128.00. This current average reflects an increase of 8.02% from the previous average price target of $131.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1738274429_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>The standing of UMB Financial among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jon Arfstrom</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$128.00</td>
<td>$128.00</td>
</tr>
<tr>
<td>Nathan Race</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$143.00</td>
<td>$142.00</td>
</tr>
<tr>
<td>Jared Shaw</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$139.00</td>
<td>$123.00</td>
</tr>
<tr>
<td>Brian Wilczynski</td>
<td>Morgan Stanley</td>
<td>Announces</td>
<td>Overweight</td>
<td>$156.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to UMB Financial. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of UMB Financial compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of UMB Financial's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/UMBF/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on UMB Financial analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind UMB Financial</h2>
<p>UMB Financial Corp, or UMBF, is a financial services holding company offering a suite of banking, asset management, and health spending solutions. Its customer base includes commercial, institutional, and personal customers across the United States. The company's banking subsidiaries own and operate banking and wealth-management centers mostly throughout the Midwest and Southwest regions of the U.S. Subsidiaries of the holding company and its lead bank, UMB Bank, include mutual fund and alternative investment services groups, single-purpose companies that deal with brokerage services and insurance, and a registered investment advisory. The bank's revenue is split nearly evenly between interest income and noninterest income.</p>
<h3>UMB Financial's Economic Impact: An Analysis</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> UMB Financial's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately <strong>8.32%</strong>. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Financials sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>30.44%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> UMB Financial's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>3.43%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>0.25%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> UMB Financial's debt-to-equity ratio is below the industry average at <strong>0.11</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


UMBF

A Glimpse Into The Expert Outlook On UMB Financial Through 4 Analysts

<p>Barrington Research  analyst James Goss   maintains Sirius XM Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIRI#NASDAQ">SIRI</a>) with a Outperform and maintains $30 price target.</p>


News

Price Target

SIRI

Barrington Research Maintains Outperform on Sirius XM Holdings, Maintains $30 Price Target

<p>Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) has outperformed the market over the past 15 years by 8.34% on an annualized basis producing an average annual return of 20.61%. Currently, Alnylam Pharmaceuticals has a market capitalization of $36.14 billion. </p>
<p><strong>Buying $1000 In ALNY:</strong> If an investor had bought $1000 of ALNY stock 15 years ago, it would be worth <strong>$16,726.61</strong> today based on a price of $280.16 for ALNY at the time of writing.</p>
<h3>Alnylam Pharmaceuticals's Performance Over Last 15 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1738274415_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Trading Ideas

ALNY

$1000 Invested In This Stock 15 Years Ago Would Be Worth This Much Today

<p>8 analysts have shared their evaluations of Pacira BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $24.62, along with a high estimate of $39.00 and a low estimate of $16.00. Observing a 15.15% increase, the current average has risen from the previous average price target of $21.38. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1738274416_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>A comprehensive examination of how financial experts perceive Pacira BioSciences is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Les Sulewski</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$25.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$18.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Serge Belanger</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$30.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Serge Belanger</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$30.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Oren Livnat</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$39.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Balaji Prasad</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$17.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Serge Belanger</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$16.00</td>
<td>$15.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Pacira BioSciences. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Pacira BioSciences compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of Pacira BioSciences's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Capture valuable insights into Pacira BioSciences's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/PCRX/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Pacira BioSciences analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>About Pacira BioSciences</h2>
<p>Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.</p>
<h3>Financial Insights: Pacira BioSciences</h3>
<p><strong>Market Capitalization Analysis:</strong> Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Pacira BioSciences's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately <strong>2.83%</strong>. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Pacira BioSciences's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of <strong>-85.11%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Pacira BioSciences's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of <strong>-17.62%,</strong> the company may encounter challenges in delivering satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>-9.06%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> Pacira BioSciences's debt-to-equity ratio is below the industry average. With a ratio of <b>0.86</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


PCRX

What 8 Analyst Ratings Have To Say About Pacira BioSciences

<p>Financial Institutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FISI#NASDAQ">FISI</a>) reported quarterly adjusted earnings of $0.55 per share which missed the analyst consensus estimate of $0.56. The company reported quarterly sales of $41.63 million which missed the analyst consensus estimate of $42.36 million by 1.71 percent. This is a 4.38 percent increase over sales of $39.89 million the same period last year. Adjusted earnings exclude loss on investment securities of $100.1M or $75M after-tax due to previously disclosed securities portfolio restructurings.</p>


Earnings

Earnings Beats

Earnings Misses

FISI

Financial Institutions Q4 Adj EPS $0.55 miss $0.56 Estimate, Sales $41.63M Miss $42.36M Estimate. Adjusted EPS excludes loss on investment securities of $100.1M or $75M after-tax due to previously disclosed securities portfolio restructurings.

Dividends

Walgreens Boots Alliance Says Its Cash Needs Over Next Several Years, Including With Respect To Litigation And Debt Refinancing, Were Important Considerations To Suspend Dividend

<p>Donaldson's advanced air filter technology is set to be featured in the next-generation Freightliner SuperTruck III, further solidifying its position at the forefront of hydrogen fuel cell innovation.</p>


Donaldson Enters Partnership With Daimler Truck North America On Hydrogen Fuel Cell Project

<p>Tigress Financial  analyst Ivan Feinseth   maintains Verizon Communications (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VZ#NYSE">VZ</a>) with a Buy and maintains $55 price target.</p>


Tigress Financial Maintains Buy on Verizon Communications, Maintains $55 Price Target

<p><strong>Atlassian</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>) just disclosed its Q2 earnings on Thursday, January 30, 2025 at 04:05 PM.</p>
<p>Here's a brief overview of the earnings report.</p>
<h3>Earnings</h3>
<p>Atlassian beat estimated earnings by 26.0%, reporting an EPS of $0.96 versus an estimate of $0.76.</p>
<p>Revenue was up $226.00 million from the same period last year.</p>
<h3>Historical Earnings Summary</h3>
<p>In the previous quarter, the company beat on EPS by $0.13, resulting in a 19.0% increase change in the share price the following day.</p>
<p>Here's a look at Atlassian's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.64</td>
<td>0.61</td>
<td>0.62</td>
<td>0.62</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.77</td>
<td>0.66</td>
<td>0.89</td>
<td>0.73</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>1.15B</td>
<td>1.13B</td>
<td>1.10B</td>
<td>1.02B</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>1.19B</td>
<td>1.13B</td>
<td>1.19B</td>
<td>1.06B</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Atlassian <a href="https://www.benzinga.com/quote/TEAM/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


TEAM

Atlassian Q2 Earnings Assessment

<p><strong>Bancorp</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBBK#NASDAQ">TBBK</a>) announced its Q4 earnings on Thursday, January 30, 2025 at 04:05 PM.</p>
<p>Here's a breakdown of the earnings report.</p>
<h3>Earnings</h3>
<p>Bancorp beat estimated earnings by 2.0%, reporting an EPS of $1.15 versus an estimate of $1.13.</p>
<p>Revenue was up $2.14 million from the same period last year.</p>
<h3>Previous Earnings Records</h3>
<p>During the previous quarter, the company missed on EPS by $0.08, leading to a 14.000000000000002% drop share price change the next day.</p>
<p>Here's a look at Bancorp's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.12</td>
<td>1.07</td>
<td>1.05</td>
<td>0.95</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.04</td>
<td>1.07</td>
<td>1.06</td>
<td>0.95</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>99.31M</td>
<td>96.41M</td>
<td>116.51M</td>
<td>90.65M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>93.73M</td>
<td>93.80M</td>
<td>94.42M</td>
<td>92.16M</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>Bancorp management provided guidance for FY 2025, expecting earnings between $5.25 and $5.25 per share.</p>
<p>To track all earnings releases for Bancorp <a href="https://www.benzinga.com/quote/TBBK/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


TBBK

Bancorp Q4 Earnings Assessment

<p><strong>Standex International</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SXI#NYSE">SXI</a>) released its Q2 earnings on Thursday, January 30, 2025 at 04:01 PM.</p>
<p>Here's what's important from the earnings announcement.</p>
<h3>Earnings</h3>
<p>Standex International beat estimated earnings by 14.000000000000002%, reporting an EPS of $1.91 versus an estimate of $1.67.</p>
<p>Revenue was up $11.41 million from the same period last year.</p>
<h3>Past Earnings Performance</h3>
<p>In the previous quarter, the company beat on EPS by $0.01, resulting in a 4.0% increase change in the share price the following day.</p>
<p>Here's a look at Standex International's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.70</td>
<td>1.72</td>
<td>1.67</td>
<td>1.72</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.71</td>
<td>1.76</td>
<td>1.75</td>
<td>1.78</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>181.39M</td>
<td>181.29M</td>
<td>180.14M</td>
<td>182.52M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>170.46M</td>
<td>180.19M</td>
<td>177.27M</td>
<td>178.40M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Standex International <a href="https://www.benzinga.com/quote/SXI/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Standex International Earnings Report: Q2 Overview

<p>The Q4 earnings report for <strong>Eastman Chemical</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMN#NYSE">EMN</a>) was released on Thursday, January 30, 2025 at 04:15 PM.</p>
<p>Here's what investors need to know about the latest announcement.</p>
<h3>Earnings</h3>
<p>Eastman Chemical beat estimated earnings by 19.0%, reporting an EPS of $1.87 versus an estimate of $1.57.</p>
<p>Revenue was up $38.00 million from the same period last year.</p>
<h3>Overview of Past Earnings</h3>
<p>Last quarter the company beat on EPS by $0.12 which was followed by a 4.0% drop in the share price the next day.</p>
<p>Here's a look at Eastman Chemical's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>2.14</td>
<td>2.01</td>
<td>1.43</td>
<td>1.30</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>2.26</td>
<td>2.15</td>
<td>1.61</td>
<td>1.31</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>2.38B</td>
<td>2.36B</td>
<td>2.29B</td>
<td>2.21B</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>2.46B</td>
<td>2.36B</td>
<td>2.31B</td>
<td>2.21B</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>Eastman Chemical management provided guidance for FY 2025, expecting earnings between $8.0 and $8.75 per share.</p>
<p>To track all earnings releases for Eastman Chemical <a href="https://www.benzinga.com/quote/EMN/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Insights into Eastman Chemical Q4 Earnings

Walgreens Boots Alliance Suspends Quarterly Dividend

<p>The earnings results for <strong>Arthur J. Gallagher</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AJG#NYSE">AJG</a>) for Q4 were made public on Thursday, January 30, 2025 at 04:15 PM.</p>
<p>Here's a comprehensive overview of the announcement.</p>
<h3>Earnings</h3>
<p>Arthur J. Gallagher beat estimated earnings by 5.0%, reporting an EPS of $2.13 versus an estimate of $2.03.</p>
<p>Revenue was up $284.00 million from the same period last year.</p>
<h3>Historical Earnings Summary</h3>
<p>Last quarter the company missed on EPS by $0.01 which was followed by a 2.0% drop in the share price the next day.</p>
<p>Here's a look at Arthur J. Gallagher's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>2.27</td>
<td>2.24</td>
<td>3.41</td>
<td>1.85</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>2.26</td>
<td>2.26</td>
<td>3.49</td>
<td>1.85</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>2.78B</td>
<td>2.76B</td>
<td>3.18B</td>
<td>2.36B</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>2.81B</td>
<td>2.77B</td>
<td>3.26B</td>
<td>2.43B</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Arthur J. Gallagher <a href="https://www.benzinga.com/quote/AJG/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Recap: Arthur J. Gallagher Q4 Earnings

<p>The earnings results for <strong>Adtalem Glb Education</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATGE#NYSE">ATGE</a>) for Q2 were made public on Thursday, January 30, 2025 at 04:15 PM.</p>
<p>Here's a comprehensive overview of the announcement.</p>
<h3>Earnings</h3>
<p>Adtalem Glb Education beat estimated earnings by 32.0%, reporting an EPS of $1.81 versus an estimate of $1.37.</p>
<p>Revenue was up $54.49 million from the same period last year.</p>
<h3>Historical Earnings Summary</h3>
<p>The company beat on EPS by $0.16 in the previous quarter, leading to a 10.0% increase share price change the next day.</p>
<p>Here's a look at Adtalem Glb Education's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.13</td>
<td>1.28</td>
<td>1.16</td>
<td>0.98</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.29</td>
<td>1.37</td>
<td>1.50</td>
<td>1.23</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>397.70M</td>
<td>398.63M</td>
<td>391.70M</td>
<td>372.79M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>417.40M</td>
<td>409.91M</td>
<td>412.66M</td>
<td>393.24M</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>Adtalem Glb Education management provided guidance for FY 2025, expecting earnings between $6.1 and $6.3 per share.</p>
<p>To track all earnings releases for Adtalem Glb Education <a href="https://www.benzinga.com/quote/ATGE/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Adtalem Global Education Inc. Common Stock

ATGE

Insights into Adtalem Glb Education Q2 Earnings

<p><strong>Boot Barn Holdings</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOOT#NYSE">BOOT</a>) just disclosed its Q3 earnings on Thursday, January 30, 2025 at 04:10 PM.</p>
<p>Here's a brief overview of the earnings report.</p>
<h3>Earnings</h3>
<p>Boot Barn Holdings beat estimated earnings by 2.0%, reporting an EPS of $2.43 versus an estimate of $2.38.</p>
<p>Revenue was up $87.77 million from the same period last year.</p>
<h3>Past Earnings Performance</h3>
<p>Last quarter the company missed on EPS by $0.0 which was followed by a 20.0% drop in the share price the next day.</p>
<p>Here's a look at Boot Barn Holdings's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2025</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.95</td>
<td>1.02</td>
<td>0.88</td>
<td>1.79</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.95</td>
<td>1.26</td>
<td>0.91</td>
<td>1.81</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>423.30M</td>
<td>411.38M</td>
<td>384.89M</td>
<td>521.36M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>425.80M</td>
<td>423.39M</td>
<td>388.46M</td>
<td>520.40M</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>Boot Barn Holdings management provided guidance for FY 2025, expecting earnings between $5.81 and $5.9 per share.</p>
<p>To track all earnings releases for Boot Barn Holdings <a href="https://www.benzinga.com/quote/BOOT/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


BOOT

Boot Barn Holdings Earnings Analysis: Q3 Recap

<p>The earnings results for <strong>Hartford Finl Servs Gr</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIG#NYSE">HIG</a>) for Q4 were made public on Thursday, January 30, 2025 at 04:15 PM.</p>
<p>Here's a comprehensive overview of the announcement.</p>
<h3>Earnings</h3>
<p>Hartford Finl Servs Gr beat estimated earnings by 11.0%, reporting an EPS of $2.94 versus an estimate of $2.64.</p>
<p>Revenue was up $479.00 million from the same period last year.</p>
<h3>Overview of Past Earnings</h3>
<p>During the previous quarter, the company missed on EPS by $0.01, leading to a 7.000000000000001% drop share price change the next day.</p>
<p>Here's a look at Hartford Finl Servs Gr's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>2.54</td>
<td>2.24</td>
<td>2.45</td>
<td>2.44</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>2.53</td>
<td>2.50</td>
<td>2.34</td>
<td>3.06</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>6.69B</td>
<td>6.57B</td>
<td>6.51B</td>
<td>6.36B</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>6.75B</td>
<td>6.49B</td>
<td>6.42B</td>
<td>6.40B</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Hartford Finl Servs Gr <a href="https://www.benzinga.com/quote/HIG/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Earnings Summary: Hartford Finl Servs Gr Q4

<p><strong>Ameris</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABCB#NYSE">ABCB</a>) just disclosed its Q4 earnings on Thursday, January 30, 2025 at 04:15 PM.</p>
<p>Here's a brief overview of the earnings report.</p>
<h3>Earnings</h3>
<p>Ameris beat estimated earnings by 16.0%, reporting an EPS of $1.38 versus an estimate of $1.19.</p>
<p>Revenue was up $28.43 million from the same period last year.</p>
<h3>Past Earnings Performance</h3>
<p>During the previous quarter, the company beat on EPS by $0.13, leading to a 3.0% drop share price change the next day.</p>
<p>Here's a look at Ameris's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.25</td>
<td>1.14</td>
<td>1.04</td>
<td>1.10</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.38</td>
<td>1.17</td>
<td>1.10</td>
<td>1.07</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>286.86M</td>
<td>272.81M</td>
<td>258.05M</td>
<td>264.66M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>283.77M</td>
<td>300.63M</td>
<td>267.27M</td>
<td>262.35M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Ameris <a href="https://www.benzinga.com/quote/ABCB/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


ABCB

Recap: Ameris Q4 Earnings

<p><strong>Financial Institutions</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FISI#NASDAQ">FISI</a>) just disclosed its Q4 earnings on Thursday, January 30, 2025 at 04:05 PM.</p>
<p>Here's a brief overview of the earnings report.</p>
<h3>Earnings</h3>
<p>Financial Institutions missed estimated earnings by -2.0%, reporting an EPS of $0.55 versus an estimate of $0.56.</p>
<p>Revenue was up $1.75 million from the same period last year.</p>
<h3>Previous Earnings Records</h3>
<p>During the previous quarter, the company beat on EPS by $0.08, leading to a 4.0% drop share price change the next day.</p>
<p>Here's a look at Financial Institutions's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.76</td>
<td>2.01</td>
<td>0.59</td>
<td>0.71</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.84</td>
<td>1.62</td>
<td>0.11</td>
<td>0.61</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>42.17M</td>
<td>45.09M</td>
<td>39.52M</td>
<td>40.32M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>40.68M</td>
<td>41.19M</td>
<td>40.08M</td>
<td>39.89M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Financial Institutions <a href="https://www.benzinga.com/quote/FISI/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Comments

Terran Orbital Corp Warrants (09/03/2028)

Terran Orbital Corp Warrants (09/03/2028) (LLAPW) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga